Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations — Stella
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
United States
USC Norris Comprehensive Cancer Center, Los Angeles, California
UCSF Medical Center at Mount Zion, San Francisco, California
Stanford Cancer Institute, Stanford, California
The University of Kansas Medical Center, Westwood, Kansas
John Hopkins University, Baltimore, Maryland
Mass General Cancer Center, Boston, Massachusetts
Karmanos Cancer Institute, Detroit, Michigan
Columbia University Irving Medical Center, New York, New York
Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee
Canada
University Health Network Princess Margaret Cancer Center, Toronto, Ontario
South Korea
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul